HBIO Harvard Bioscience Inc.

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET

HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. 

Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number. 

Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website .

Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the section of Harvard Bioscience’s website. 

About Harvard Bioscience 

Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in the United States, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world.

For more information, please visit our website at .

Company Contact:

Mark Frost

Interim Chief Financial Officer

(508) 893-3120



EN
30/10/2025

Underlying

HBIOHarvard Bioscience Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harvard Bioscience Inc.

 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Third Quarter 2025 Financial Results

Harvard Bioscience Announces Third Quarter 2025 Financial Results Reports Q3 2025 Revenues of $20.6M, Gross Margin of 58.4%, and Positive Cash Provided by OperationsCompany Expects to Refinance or Repay the Debt in the Fourth QuarterFourth Quarter 2025 Guidance Reflects Increased Demand and Backlog, Improved Operations and Strong Financial Discipline HOLLISTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the third quarter and nine months ended September 30, 2025. “Our third-quarter performance hig...

3h / 17m 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Ca...

Harvard Bioscience Schedules Third Quarter 2025 Earnings Conference Call for November 6, 2025 at 8:00 AM ET HOLLISTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended September 30, 2025, before the market opens on November 6, 2025, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register . Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like...

October 30, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Expands Distribution Agreement with Fisher Scientif...

Harvard Bioscience Expands Distribution Agreement with Fisher Scientific to Include United States - Strategic expansion with trusted partner enhances customer reach HOLLISTON, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”), a leading provider of innovative laboratory equipment, is pleased to announce the expansion of its distribution agreement with Fisher Scientific, a part of Thermo Fisher Scientific, one of the world’s largest and most trusted scientific suppliers. Under this new agreement, Fisher Scientific ...

September 16, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board ...

Harvard Bioscience Announces Appointment of Stephen DeNelsky to Board of Directors Veteran life sciences industry financing leader appointed as new Board member HOLLISTON, Mass., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company” or “Harvard Bioscience”) today announced the appointment of Stephen DeNelsky to its Board of Directors, effective September 5, 2025. Mr. DeNelsky will also serve on the Board’s Nominating and Governance Committee. “We are pleased to announce Steve as the newest member of our Board of Directors at such an important time fo...

September 9, 2025 1 EN
 PRESS RELEASE
Free
HBIO Harvard Bioscie...

Harvard Bioscience Announces Second Quarter 2025 Financial Results

Harvard Bioscience Announces Second Quarter 2025 Financial Results Reports Q2 2025 Revenues of $20.5M, Gross Margin of 56.4%, and Positive Cash Provided by OperationsThird Quarter 2025 Guidance Reflects Improved Operations and Strong Financial DisciplineNew Credit Amendment Signed, Extending Refinance Deadline to December 5th HOLLISTON, Mass., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2025. “We made solid progress in the second quarter exceeding our rev...

August 11, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch